Hyemi Kwon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hyemi Kwon has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Eun-Jung Rhee
Division of Endocrinology and Metabolism, Department of Internal Medicine Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine Seoul Republic of Korea
5 shared publications - Tae Yong Kim
Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine
5 shared publications - Won-Young Lee
Division of Endocrinology and Metabolism, Department of Internal Medicine Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine Seoul Republic of Korea
5 shared publications - Min Ji Jeon
Department of Internal Medicine, Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
4 shared publications - Won Bae Kim
Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
4 shared publications - Young Kee Shong
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
4 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 41 (5) , 696-705
All-Cause Mortality and Secondary Malignancy in Patients with Pheochromocytoma/Paraganglioma
Background: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that can be fatal if not diagnosed early or adequately managed. This study investigated the risk of all-cause mortality and secondary malignancies in patients with PPGL compared to age- and sex-matched controls without PPGL.Methods: This nationwide population-based cohort study included 1,672 patients with PPGL and 16,790 controls with a median follow-up of approximately 7.1 years. A Cox proportional hazard model was used to estimate the adjusted hazard ratio (HR) and 95% confidence intervals (CI).Results: The mean age was 46.5 years and 50.5% were male. All-cause mortality was identified in 118 patients with PPGL (7.06%) and 749 controls (4.46%) during the follow-up period. The incidence of all-cause mortality in patients with PPGL was significantly higher than that in controls (9.92 per 1,000 person-years vs. 6.49 per 1,000 person-years, P=0.0003). The risk of all-cause mortality was significantly higher in patients with PPGL than in the controls (HR, 1.372; 95% CI, 1.124 to 1.675). The risk of secondary malignancies was significantly higher in patients with PPGL than in controls (HR, 1.612; 95% CI, 1.33 to 1.954) after adjusting. Among the various cancer subtypes, thyroid and prostate cancers were observed more frequently in PPGL patients, and these findings should be interpreted as descriptive trends.Conclusion: Patients with PPGL exhibited significantly increased risks of all-cause mortality and secondary malignancies compared with controls, highlighting the importance of appropriate assessment and follow-up.
- 31 October 2026
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 41 (5) , 696-705
Open AccessAll-Cause Mortality and Secondary Malignancy in Patients with Pheochromocytoma/Paraganglioma
Background: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that can be fatal if not diagnosed early or adequately managed. This study investigated the risk of all-cause mortality and secondary malignancies in patients with PPGL compared to age- and sex-matched controls without PPGL.Methods: This nationwide population-based cohort study included 1,672 patients with PPGL and 16,790 controls with a median follow-up of approximately 7.1 years. A Cox proportional hazard model was used to estimate the adjusted hazard ratio (HR) and 95% confidence intervals (CI).Results: The mean age was 46.5 years and 50.5% were male. All-cause mortality was identified in 118 patients with PPGL (7.06%) and 749 controls (4.46%) during the follow-up period. The incidence of all-cause mortality in patients with PPGL was significantly higher than that in controls (9.92 per 1,000 person-years vs. 6.49 per 1,000 person-years, P=0.0003). The risk of all-cause mortality was significantly higher in patients with PPGL than in the controls (HR, 1.372; 95% CI, 1.124 to 1.675). The risk of secondary malignancies was significantly higher in patients with PPGL than in controls (HR, 1.612; 95% CI, 1.33 to 1.954) after adjusting. Among the various cancer subtypes, thyroid and prostate cancers were observed more frequently in PPGL patients, and these findings should be interpreted as descriptive trends.Conclusion: Patients with PPGL exhibited significantly increased risks of all-cause mortality and secondary malignancies compared with controls, highlighting the importance of appropriate assessment and follow-up.
- Open Access
- 15 January 2026
- Published by Bioscientifica in European Thyroid Journal
- Vol. 15 (1)
Artificial intelligence-assisted risk stratification of thyroid nodules with atypia of undetermined significance
Objective: Given the limitations of conventional approaches in managing indeterminate thyroid nodules, there remains an unmet need for non-invasive assistant tools to improve risk stratification. This study aimed to evaluate the clinical applicability of an artificial intelligence (AI) model for thyroid nodules with atypia of undetermined significance (AUS) cytology. Methods: We retrospectively reviewed patients who underwent fine-needle aspiration (FNA) for thyroid nodules between January 2019 and December 2020 across five medical institutions in Korea. Nodules initially diagnosed as AUS and later confirmed as benign or malignant were included. A previously developed deep learning-based AI model, AI-Thyroid, was employed to provide binary classifications (benign or malignant) and malignancy risk estimates. Results: A total of 165 thyroid nodules were analyzed. The median (interquartile range) longest diameter was 1.30 cm (0.80–2.10), and the malignancy rate of the cohort was 39%. In binary classification tasks, the model achieved a sensitivity of 0.91 and a negative predictive value of 0.87. The area under the curve (AUC) based on estimated malignancy risk was 0.75 (95% confidence interval (CI): 0.68–0.83), and the AUC derived from K-TIRADS categories 2–5 was 0.76 (95% CI: 0.69–0.83), indicating comparable diagnostic accuracy with the traditional scoring system. Subgroup analyses demonstrated that the model achieved a sensitivity of 98% in nodules smaller than 1.5 cm. Conclusion: AI-assisted ultrasound analysis offers supplementary diagnostic information for thyroid nodules with AUS cytology. Its high sensitivity and negative predictive value may assist clinicians in decision-making processes, particularly for small, low-risk thyroid nodules.
- 15 January 2026
- Published by Bioscientifica in European Thyroid Journal
- Vol. 15 (1)
Open AccessArtificial intelligence-assisted risk stratification of thyroid nodules with atypia of undetermined significance
Objective: Given the limitations of conventional approaches in managing indeterminate thyroid nodules, there remains an unmet need for non-invasive assistant tools to improve risk stratification. This study aimed to evaluate the clinical applicability of an artificial intelligence (AI) model for thyroid nodules with atypia of undetermined significance (AUS) cytology. Methods: We retrospectively reviewed patients who underwent fine-needle aspiration (FNA) for thyroid nodules between January 2019 and December 2020 across five medical institutions in Korea. Nodules initially diagnosed as AUS and later confirmed as benign or malignant were included. A previously developed deep learning-based AI model, AI-Thyroid, was employed to provide binary classifications (benign or malignant) and malignancy risk estimates. Results: A total of 165 thyroid nodules were analyzed. The median (interquartile range) longest diameter was 1.30 cm (0.80–2.10), and the malignancy rate of the cohort was 39%. In binary classification tasks, the model achieved a sensitivity of 0.91 and a negative predictive value of 0.87. The area under the curve (AUC) based on estimated malignancy risk was 0.75 (95% confidence interval (CI): 0.68–0.83), and the AUC derived from K-TIRADS categories 2–5 was 0.76 (95% CI: 0.69–0.83), indicating comparable diagnostic accuracy with the traditional scoring system. Subgroup analyses demonstrated that the model achieved a sensitivity of 98% in nodules smaller than 1.5 cm. Conclusion: AI-assisted ultrasound analysis offers supplementary diagnostic information for thyroid nodules with AUS cytology. Its high sensitivity and negative predictive value may assist clinicians in decision-making processes, particularly for small, low-risk thyroid nodules.
- Open Access
- 30 July 2025
- Published by MDPI AG in Preprints.org
Glomerular Hyperfiltration as a Sentinel Marker for Chronic Kidney Disease and Liver Fibrosis in MASLD/MAFLD: Longitudinal Evidence
Background: The interplay between glomerular hyperfiltration (GHF) and renal dysfunction and hepatic fibrosis in metabolic-associated steatotic (or fatty) liver disease (MASLD or MAFLD) remains insufficiently understood. Therefore, we examined the association in a relatively healthy population. Methods: Between 2002 and 2019, 47,741 adults (18–70 years old) participated in the study and underwent baseline liver ultrasonography and annual renal function assessments. Hepatic steatosis was diagnosed using ultrasonography, and GHF was defined as an estimated residual glomerular filtration rate exceeding the 95th percentile based on age- and sex-specific thresholds. The progression of liver fibrosis was assessed using noninvasive markers. Chronic kidney disease (CKD) and advanced liver fibrosis progression were the primary and secondary endpoints, respectively. Results: Patients with MASLD but without GHF did not exhibit an increased risk of CKD progression. However, GHF was independently associated with a higher risk of CKD progression, particularly in patients with MASLD (adjusted hazard ratio (HR): 3.88 [95% CI 3.66–4.11]). GHF alone led to a slight increase in advanced liver fibrosis risk, whereas its presence in patients with MASLD significantly exacerbated fibrosis progression (adjusted HR, 1.36 [95% CI 1.24–1.48]). In patients with coexisting GHF and MASLD, CKD development was associated with a 24% additional risk of advanced liver fibrosis (adjusted HR, 1.24; 95% CI, 1.19–1.29). Consistent findings were also noted based on the MAFLD definition. Conclusions: GHF is associated with future CKD and liver fibrosis progression, serving as a prognostic marker in patients with MASLD (or MAFLD), emphasizing the need for timely identification and monitoring.
- 30 July 2025
- Published by MDPI AG in Preprints.org
Open AccessGlomerular Hyperfiltration as a Sentinel Marker for Chronic Kidney Disease and Liver Fibrosis in MASLD/MAFLD: Longitudinal Evidence
Background: The interplay between glomerular hyperfiltration (GHF) and renal dysfunction and hepatic fibrosis in metabolic-associated steatotic (or fatty) liver disease (MASLD or MAFLD) remains insufficiently understood. Therefore, we examined the association in a relatively healthy population. Methods: Between 2002 and 2019, 47,741 adults (18–70 years old) participated in the study and underwent baseline liver ultrasonography and annual renal function assessments. Hepatic steatosis was diagnosed using ultrasonography, and GHF was defined as an estimated residual glomerular filtration rate exceeding the 95th percentile based on age- and sex-specific thresholds. The progression of liver fibrosis was assessed using noninvasive markers. Chronic kidney disease (CKD) and advanced liver fibrosis progression were the primary and secondary endpoints, respectively. Results: Patients with MASLD but without GHF did not exhibit an increased risk of CKD progression. However, GHF was independently associated with a higher risk of CKD progression, particularly in patients with MASLD (adjusted hazard ratio (HR): 3.88 [95% CI 3.66–4.11]). GHF alone led to a slight increase in advanced liver fibrosis risk, whereas its presence in patients with MASLD significantly exacerbated fibrosis progression (adjusted HR, 1.36 [95% CI 1.24–1.48]). In patients with coexisting GHF and MASLD, CKD development was associated with a 24% additional risk of advanced liver fibrosis (adjusted HR, 1.24; 95% CI, 1.19–1.29). Consistent findings were also noted based on the MAFLD definition. Conclusions: GHF is associated with future CKD and liver fibrosis progression, serving as a prognostic marker in patients with MASLD (or MAFLD), emphasizing the need for timely identification and monitoring.
- Open Access
- 30 May 2025
- Published by Korean Thyroid Association in International Journal of Thyroidology
- Vol. 18 (1) , 65-79
2025 Korean Thyroid Association Management Guidelines for Radioactive Iodine Therapy in Patients with Hyperthyroidism
Kyeong Jin Kim, Eyun Song, Mijin Kim, Hyemi Kwon, Eu Jeong Ku, Hyun Woo Kwon, Jee Hee Yoon, Eun Kyung Lee, Won Woo Lee, Young Joo Park, Dong-Jun Lim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Tae Yong Kim, Sin Gon Kim, Dong Gyu Na and Jee Soo Kim. Int J Thyroidol 2025;18:65-79. https://doi.org/10.11106/ijt.2025.18.1.65
- 30 May 2025
- Published by Korean Thyroid Association in International Journal of Thyroidology
- Vol. 18 (1) , 65-79
Open Access2025 Korean Thyroid Association Management Guidelines for Radioactive Iodine Therapy in Patients with Hyperthyroidism
Kyeong Jin Kim, Eyun Song, Mijin Kim, Hyemi Kwon, Eu Jeong Ku, Hyun Woo Kwon, Jee Hee Yoon, Eun Kyung Lee, Won Woo Lee, Young Joo Park, Dong-Jun Lim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Tae Yong Kim, Sin Gon Kim, Dong Gyu Na and Jee Soo Kim. Int J Thyroidol 2025;18:65-79. https://doi.org/10.11106/ijt.2025.18.1.65
- Open Access
- 31 August 2023
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 38 (4) , 392-394
The Current Status of Hyperthyroidism in Korea
- 31 August 2023
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 38 (4) , 392-394
Open AccessThe Current Status of Hyperthyroidism in Korea
- Open Access
- 31 December 2022
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 37 (6) , 839-850
Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.
- 31 December 2022
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 37 (6) , 839-850
Open AccessImmune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.
- Open Access
- 30 April 2022
- Published by Korean Society of Cardiovascular Disease Prevention in Cardiovascular Prevention and Pharmacotherapy
- Vol. 4 (2) , 75-86
Effects of exercise on reducing diabetes risk in Korean women according to menopausal status
Background: Exercise and estrogen play key roles in preventing diabetes and obesity. Women’s risk of diabetes could increase due to the loss of the protective effect of estrogen after menopause. Therefore, we investigated the relationship of the intensity and frequency of exercise with diabetes risk in Korean women.Methods: Hazard ratios (HRs) for the development of diabetes were analyzed in 926,807 premenopausal and 1,188,346 postmenopausal women without diabetes over the age of 40 who underwent the Korean National Health Examination in 2009 and were followed up until 2018. The number of days of physical activity according to exercise intensity and metabolic equivalent of task-minutes per week (MET-min/wk) were calculated.Results: In total, 38,096 premenopausal (4.1%) and 120,605 postmenopausal (10.2%) women were newly diagnosed with diabetes. Regardless of menopausal history, the risk of diabetes was significantly lower in groups with higher MET-min/wk than in sedentary participants (0 MET-min/wk, reference), although this effect disappeared in postmenopausal women with the highest level of MET-min/wk (MET-min/wk ≥1,500) after adjusting for all variables (HR, 1.0; 95% confidence interval, 0.97–1.02). Participants who exercised for more than 1 day per week had a significantly lower risk of diabetes, regardless of the intensity. However, this benefit was lost in women with near-daily exercise (≥6 days/wk).Conclusions: Exercise was effective in preventing diabetes in both premenopausal and postmenopausal women. A moderate amount of exercise should be actively encouraged to lower the risk of diabetes in women, especially after menopause, while simultaneously considering the insignificant benefits of excessive exercise.
- 30 April 2022
- Published by Korean Society of Cardiovascular Disease Prevention in Cardiovascular Prevention and Pharmacotherapy
- Vol. 4 (2) , 75-86
Open AccessEffects of exercise on reducing diabetes risk in Korean women according to menopausal status
Background: Exercise and estrogen play key roles in preventing diabetes and obesity. Women’s risk of diabetes could increase due to the loss of the protective effect of estrogen after menopause. Therefore, we investigated the relationship of the intensity and frequency of exercise with diabetes risk in Korean women.Methods: Hazard ratios (HRs) for the development of diabetes were analyzed in 926,807 premenopausal and 1,188,346 postmenopausal women without diabetes over the age of 40 who underwent the Korean National Health Examination in 2009 and were followed up until 2018. The number of days of physical activity according to exercise intensity and metabolic equivalent of task-minutes per week (MET-min/wk) were calculated.Results: In total, 38,096 premenopausal (4.1%) and 120,605 postmenopausal (10.2%) women were newly diagnosed with diabetes. Regardless of menopausal history, the risk of diabetes was significantly lower in groups with higher MET-min/wk than in sedentary participants (0 MET-min/wk, reference), although this effect disappeared in postmenopausal women with the highest level of MET-min/wk (MET-min/wk ≥1,500) after adjusting for all variables (HR, 1.0; 95% confidence interval, 0.97–1.02). Participants who exercised for more than 1 day per week had a significantly lower risk of diabetes, regardless of the intensity. However, this benefit was lost in women with near-daily exercise (≥6 days/wk).Conclusions: Exercise was effective in preventing diabetes in both premenopausal and postmenopausal women. A moderate amount of exercise should be actively encouraged to lower the risk of diabetes in women, especially after menopause, while simultaneously considering the insignificant benefits of excessive exercise.
- Open Access
- 31 January 2022
- Published by Korean Society of Cardiovascular Disease Prevention in Cardiovascular Prevention and Pharmacotherapy
- Vol. 4 (1) , 42-55
Effects of physical activity on cardiovascular outcomes and mortality in Korean patients with diabetes: a nationwide population-based cohort study
Background: Since a sedentary lifestyle is considered a modifiable risk factor for cardiovascular disease (CVD), physical activity (PA) is recommended for type 2 diabetes mellitus (T2DM) patients to prevent CVD. We investigated the association between different levels of PA and the risk for CVD and all-cause mortality in patients with T2DM using nationwide data. Methods: We examined health examination data and claims records of 2,745,637 participants with T2DM at baseline from the Korean National Health Insurance Service who underwent health examinations between 2009 and 2012. We excluded subjects with a history of myocardial infarction or stroke. Each participant was asked to report their weekly PA levels according to three categories: vigorous, moderate, and walking. The incidence of CVD and death was analyzed until 2017.Results: The risk of CVD was lower in regular exercisers than in nonexercisers after adjusting for confounding variables. A dose-response trend was evident in the association between the degree of PA and CVD risk. All categories of PA were inversely associated with CVD risk and mortality. The reduction in CVD risk and all-cause mortality was more profound in patients aged ≥65 years. Conclusions: Augmenting PA might have positive effects on the prevention of CVD and all-cause death, especially in the elderly. The benefits of PA were consistently observed in various subgroups regardless of the presence of chronic conditions. Therefore, clinicians should encourage elderly patients with T2DM to increase their daily PA.
- 31 January 2022
- Published by Korean Society of Cardiovascular Disease Prevention in Cardiovascular Prevention and Pharmacotherapy
- Vol. 4 (1) , 42-55
Open AccessEffects of physical activity on cardiovascular outcomes and mortality in Korean patients with diabetes: a nationwide population-based cohort study
Background: Since a sedentary lifestyle is considered a modifiable risk factor for cardiovascular disease (CVD), physical activity (PA) is recommended for type 2 diabetes mellitus (T2DM) patients to prevent CVD. We investigated the association between different levels of PA and the risk for CVD and all-cause mortality in patients with T2DM using nationwide data. Methods: We examined health examination data and claims records of 2,745,637 participants with T2DM at baseline from the Korean National Health Insurance Service who underwent health examinations between 2009 and 2012. We excluded subjects with a history of myocardial infarction or stroke. Each participant was asked to report their weekly PA levels according to three categories: vigorous, moderate, and walking. The incidence of CVD and death was analyzed until 2017.Results: The risk of CVD was lower in regular exercisers than in nonexercisers after adjusting for confounding variables. A dose-response trend was evident in the association between the degree of PA and CVD risk. All categories of PA were inversely associated with CVD risk and mortality. The reduction in CVD risk and all-cause mortality was more profound in patients aged ≥65 years. Conclusions: Augmenting PA might have positive effects on the prevention of CVD and all-cause death, especially in the elderly. The benefits of PA were consistently observed in various subgroups regardless of the presence of chronic conditions. Therefore, clinicians should encourage elderly patients with T2DM to increase their daily PA.
- Open Access
- 30 June 2020
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 35 (2) , 396-406
Serum Adiponectin and Progranulin Level in Patients with Benign Thyroid Nodule or Papillary Thyroid Cancer
Obesity is associated with thyroid cancer risk. Adiponectin has insulin-sensitizing and anti-inflammatory effects, while progranulin is associated with inflammation and tumorigenesis. We investigated serum adiponectin and progranulin levels in patients with benign thyroid nodule (benign group) and papillary thyroid cancer (PTC; PTC group). The associations between these levels and the clinicopathological features of PTC were evaluated. We included 157 patients who underwent thyroid surgery (17% of benign and 83% of PTC group). Clinicopathological features including size, lymph node metastasis, extrathyroidal extension (ETE), multifocality, American Thyroid Association risk stratification were evaluated. The age was 42.0 years, and 69% were female. Serum adiponectin and progranulin levels were 6.3 μg/mL and 101.5 ng/mL in the benign group and 5.4 μg/mL and 106.1 ng/mL in the PTC group, respectively (P=0.6 and P=0.4, respectively). Serum adiponectin levels showed no significant differences according to clinicopathological features of PTC. The proportions of patients with primary tumor size >1 cm were 3%, 5%, 8%, and 8% according to serum progranulin level quartiles, respectively (P=0.03). The proportions of patients with microscopic/gross ETE were 8%/0%, 9%/1%, 11%/1%, and 11%/2% according to serum progranulin level quartiles, respectively. Median serum progranulin level was significantly higher in patients with PTC >1 cm than in patients with papillary thyroid microcarcinoma (P=0.04, 115.3 ng/mL and 104.7 ng/mL, respectively). Serum adiponectin and progranulin levels showed no significant difference between benign and PTC groups. Increased serum progranulin levels were significantly associated with PTC >1 cm and microscopic and gross ETE.
- 30 June 2020
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 35 (2) , 396-406
Open AccessSerum Adiponectin and Progranulin Level in Patients with Benign Thyroid Nodule or Papillary Thyroid Cancer
Obesity is associated with thyroid cancer risk. Adiponectin has insulin-sensitizing and anti-inflammatory effects, while progranulin is associated with inflammation and tumorigenesis. We investigated serum adiponectin and progranulin levels in patients with benign thyroid nodule (benign group) and papillary thyroid cancer (PTC; PTC group). The associations between these levels and the clinicopathological features of PTC were evaluated. We included 157 patients who underwent thyroid surgery (17% of benign and 83% of PTC group). Clinicopathological features including size, lymph node metastasis, extrathyroidal extension (ETE), multifocality, American Thyroid Association risk stratification were evaluated. The age was 42.0 years, and 69% were female. Serum adiponectin and progranulin levels were 6.3 μg/mL and 101.5 ng/mL in the benign group and 5.4 μg/mL and 106.1 ng/mL in the PTC group, respectively (P=0.6 and P=0.4, respectively). Serum adiponectin levels showed no significant differences according to clinicopathological features of PTC. The proportions of patients with primary tumor size >1 cm were 3%, 5%, 8%, and 8% according to serum progranulin level quartiles, respectively (P=0.03). The proportions of patients with microscopic/gross ETE were 8%/0%, 9%/1%, 11%/1%, and 11%/2% according to serum progranulin level quartiles, respectively. Median serum progranulin level was significantly higher in patients with PTC >1 cm than in patients with papillary thyroid microcarcinoma (P=0.04, 115.3 ng/mL and 104.7 ng/mL, respectively). Serum adiponectin and progranulin levels showed no significant difference between benign and PTC groups. Increased serum progranulin levels were significantly associated with PTC >1 cm and microscopic and gross ETE.
- Open Access
- 1 January 2019
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 34 (1) , 93-94
Letter: Thyroid-Stimulating Hormone Reference Ranges in the First Trimester of Pregnancy in an Iodine-Sufficient Country (Endocrinol Metab 2018;33:466-72, Carmen Castillo et al.)
Kwon H. Endocrinol Metab. 2019 Mar;34(1):93-94. https://doi.org/10.3803/EnM.2019.34.1.93
- 1 January 2019
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 34 (1) , 93-94
Open AccessLetter: Thyroid-Stimulating Hormone Reference Ranges in the First Trimester of Pregnancy in an Iodine-Sufficient Country (Endocrinol Metab 2018;33:466-72, Carmen Castillo et al.)
Kwon H. Endocrinol Metab. 2019 Mar;34(1):93-94. https://doi.org/10.3803/EnM.2019.34.1.93